Review Article

JOURNAL OF DRUG REACTIONS
An international online peer reviewed Journal
Content available at www.cognixpress.in Online ISSN: 3139-4132

MEDICATION SAFETY IN PREGNANCY: A COMPREHENSIVE REVIEW OF RISKS AND MANAGEMENT APPROACHES

Y. VENKATA LAKSHMI KEERTHY, G. VENKATA NAGARAJU

**Department of Pharmacy Practice, Hindu College of Pharmacy, Guntur.*

***Corresponding Author**
Y. Venkata Lakshmi Keerthy

Article History: 06.01.2026 Received: 11.02.2026 Revised: Accepted: 24.03.2026

ABSTRACT
Medication use during pregnancy presents complex clinical challenges because of the necessity to balance maternal benefit against fetal risk. Physiological changes in pregnancy influence pharmacokinetics and pharmacodynamics, while the potential for teratogenicity, fetotoxicity, and perinatal complications warrants careful risk-assessment and management. This review outlines the underlying risk mechanisms, stages of gestation relevant to drug exposure, common maternal conditions requiring therapy, principles of prescribing in pregnancy, major classes of concern (infectious disease agents, cardiovascular drugs, psycho-therapeutics, analgesics, anti-epileptics), and management strategies including pre-conception counselling, monitoring, deprescribing, and use of safety registries. Emerging approaches such as post-marketing surveillance, pregnancy registries, physiologically-based pharmacokinetic modelling, and pharmacogenomic frameworks are also reviewed. The aim is to provide a comprehensive, structured overview to guide clinicians in safe medication management for pregnant women, highlighting current evidence gaps and future directions.

Keywords: Pregnancy, medication safety, teratogenicity, pharmacokinetics, prescribing in pregnancy, fetal risk, maternal therapy, pregnancy registries, pharmacovigilance, management strategies.

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License. Copyright © 2026 Author(s) retains the copyright of this article.

INTRODUCTION

Pregnancy is a unique physiological state that requires simultaneous management of maternal and fetal health. Untreated maternal conditions, such as hypertension, epilepsy, infection, and psychiatric disorders, may significantly compromise both maternal and fetal outcomes [1–3]. At the same time, many medications cross the placenta or alter maternal physiology, potentially leading to congenital anomalies, growth restriction, preterm birth, or neonatal complications [4,5].

The historical tragedy of Thalidomide exposure in the late 1950s and early 1960s highlighted the importance of drug safety during pregnancy and catalyzed regulatory reforms [6]. Despite decades of progress, fewer than 10% of drugs approved since 1980 have sufficient human pregnancy safety information [1,2]. Clinicians must rely on mechanistic understanding, registry data, case reports, and post-marketing pharmacovigilance when prescribing medications to pregnant women [4,5,7].

PHYSIOLOGICAL AND PHARMACOKINETIC CONSIDERATIONS IN PREGNANCY

Pregnancy induces profound changes in maternal physiology that significantly impact drug pharmacokinetics, including absorption, distribution, metabolism, and excretion (ADME) [8,9].

Absorption: Gastric pH and delayed gastric emptying may alter drug absorption [9].

Distribution: Plasma volume increases by 30–50%, lowering plasma concentrations for hydrophilic drugs. Albumin levels decrease, increasing the free fraction of protein-bound drugs [8,10].

Metabolism: Hepatic enzyme activity may increase or decrease depending on the enzyme system. CYP3A4 activity generally increases, while CYP1A2 decreases [10].

Excretion: Glomerular filtration rate increases, accelerating renal drug clearance [8,11].

Placental transfer is influenced by molecular weight (drugs <500 Da cross readily), lipid solubility, protein

binding, and placental metabolism [10,11]. The fetus may be exposed to parent drugs and active metabolites. Some drugs may constrict uterine or placental vessels, impairing nutrient and oxygen exchange [11].

Timing of drug exposure is critical:

First trimester (weeks 3–8): Highest risk for teratogenesis due to organogenesis [12].

Second and third trimesters: Risk of fetal growth restriction, preterm birth, or functional deficits [13].

RISK MECHANISMS

A. Teratogenicity

Teratogens disrupt normal fetal development, causing structural or functional anomalies. Risk depends on timing, dose, maternal and fetal genetics, and biological plausibility [12,13]. Classical examples include thalidomide causing limb defects and isotretinoin causing craniofacial abnormalities [6,15,16].

B. Fetotoxicity and Functional Effects

Exposure may result in intrauterine growth restriction, placental dysfunction, fetal arrhythmias, or neurodevelopmental disorders [1,2,12]. Certain antiepileptics have been linked to cognitive impairments in offspring [7,8].

C. Neonatal and Perinatal Effects

Late-pregnancy exposure can cause neonatal respiratory depression, hypoglycemia, bleeding, or withdrawal syndromes [7,9].

D. Background Risk

Baseline risk of congenital anomalies is ~2–3%, and spontaneous miscarriage occurs in ~10–20% of pregnancies [6,7]

PRINCIPLES OF SAFE PRESCRIBING IN PREGNANCY

Key principles include [6–10]:

1. Prescribe only when maternal benefit outweighs fetal risk.
2. Use the minimal effective dose for the shortest duration.
3. Prefer drugs with established safety data; avoid new or untested medications.
4. Avoid known teratogens and polypharmacy.
5. Engage in shared decision-making with informed counselling.
6. Conduct pre-conception planning for chronic conditions.
7. Monitor maternal condition and adjust dosages as pregnancy progresses.

ASSESSMENT AND CLASSIFICATION OF MEDICATION RISK

FDA replaced A–X categories with the Pregnancy and Lactation Labeling Rule (PLLR), providing narrative risk summaries and clinical guidance [11]. EMA emphasizes post-marketing surveillance and pregnancy registries [11]. Most data is observational due to exclusion of pregnant women from pre-licensing trials [6,12].

COMMON THERAPEUTIC AREAS AND DRUG CLASSES OF CONCERN

Infectious Diseases and Antimicrobial Therapy

Safe options include penicillins and cephalosporins; tetracyclines and fluoroquinolones should be avoided [12,13].

Cardiovascular and Hypertensive Disorders

Hypertension poses risk for pre-eclampsia, fetal growth restriction, and preterm delivery. ACE inhibitors are contraindicated; labetalol, methyldopa, and nifedipine are preferred [10,14]. Mendelian randomization studies have examined safety of beta-blockers and calcium-channel blockers in pregnancy [17].

Neurological Disorders and Anti-Epileptic Drugs (AEDs)

Uncontrolled epilepsy increases maternal and fetal risks. Valproate is highly teratogenic; lamotrigine or levetiracetam is safer [7,8]. Monotherapy, lowest effective dose, and high-dose folate supplementation are recommended [12,18].

Psychiatric Medications

Maternal depression carries perinatal risks; SSRIs may cause neonatal adaptation syndrome but continuation is often safer than abrupt discontinuation [13,15]. Systematic reviews support careful risk–benefit assessment [18].

Analgesics and OTC Medications

Acetaminophen is first-line; NSAIDs should be avoided in late pregnancy [4,9].

Autoimmune and Immunosuppressant Therapy

Methotrexate and mycophenolate are teratogenic; azathioprine and hydroxychloroquine can be used with monitoring [6,13].

Table 1: Common Drug Classes and Pregnancy Safety

Drug Class	Common Examples	Safety in Pregnancy	Trimester Consideration
Antibiotics	Penicillin, Cephalosporin	safe	All trimesters
Antiepileptics	Valproate, Lamotrigine	Valproate high risk; Lamotrigine safer	Avoid valproate in first trimester
Antihypertensives	Labetalol, Methyldopa	Generally safe	All trimesters
NSAIDs	Ibuprofen	Avoid late 2^{nd}-3^{rd} trimester	3^{rd} trimester
SSRIs	Sertraline,	Relatively	All

	Fluoxetine	safe	trimesters
Immunosuppressants	Azathioprine, Methotrexate	Azathioprine safer, Methotrexate contraindicated	1st trimester critical

PRE-CONCEPTION PLANNING AND COUNSELLING

1. Review all medications (prescription, OTC, herbal) [15,16].
2. Switch to safer alternatives pre-conception [18].
3. High-dose folate supplementation, especially for antiepileptics [12,18].
4. Contraception for teratogenic drugs such as isotretinoin [15,16].

MONITORING AND MANAGEMENT DURING PREGNANCY

1. Maternal disease control and drug level assessment [7–9,18].
2. Foetal growth and anatomy scans for high-risk exposure.
3. Dose adjustments as maternal pharmacokinetics evolve.
4. Postpartum planning including breastfeeding considerations [10,12].

STRATEGIES FOR MITIGATING RISK

1. Use safest agents, lowest effective dose, shortest duration [4,5,9].
2. Avoid teratogens and polypharmacy [4,5,9].
3. Document informed consent and alternatives [4,5].
4. Utilize pregnancy registries [2,12].
5. Multidisciplinary care for complex cases [3,6].
6. Educate patients on adverse events [16].

EMERGING APPROACHES AND EVIDENCE GAPS

1. PBPK modelling and pharmacogenomics to individualize therapy [9–11,18].
2. Large-scale registries for post-marketing safety [12,13].
3. Ethical and methodological challenges remain [12,13].

CASE ILLUSTRATIONS

1. **Anti-epileptic therapy**: Switch valproate to lamotrigine pre-conception, monotherapy, high-dose folate [7,12].

2. **Hypertension:** Switch ACE inhibitor to labetalol; monitor maternal BP and fetal growth [10,14,17].

3. **Maternal depression**: Continue SSRIs under monitoring [13,15,18].

CONCLUSION

Medication safety in pregnancy requires balancing maternal benefit against fetal risk. Evidence-informed prescribing, dose minimization, avoidance of teratogens, pre-conception counselling, and multidisciplinary care are essential [1–18]. Emerging tools like pregnancy registries, PBPK models, and pharmacogenomics promise safer strategies and improved maternal-fetal outcomes.

FUNDING

Nil

INFORM CONSENT

Not Applicable

ACKNOWLEDGEMENT

Not Declared

ETHICAL STATEMENT

Not Applicable

REFERENCES

1. Jin J. Safety of medications used during pregnancy. *JAMA.* 2024;331(7):600–602.
2. Author(s). The use of medication in pregnancy. *PMC.* 2019.
3. Gunatilake R, Patil A. Drug safety in pregnancy. In: *Gynecology and Obstetrics*. MSD Manual; 2023.
4. Alwan S, Grant KS. Maternal medication use in pregnancy: a narrative review. *Pharmacoepidemiology.* 2024;3(4):336–349.
5. The risks and principles of prescribing in pregnancy. Specialist Pharmacy Service; 2025.
6. Stephens S, et al. Prescribing in pregnant women: guide to general principles. *Pharm Soc Bull.* 2009.
7. Hansen WF, et al. Safe prescribing practices in pregnancy and lactation. *PMC.* 2002.
8. El Shamy T, Tamizian O. Principles of prescribing in pregnancy. *Obstet Gynaecol Reprod Med.* 2018;28(5):139–142.
9. Sahu D, Rao VS. Pharmacokinetics and pharmacodynamics of medications used in pregnant women: a systematic review. *J Neonatal Surg.* 2025;14(1 Suppl):276–283.
10. Hebert MF. Impact of pregnancy on pharmacokinetics of medications. *J Popul Ther Clin Pharmacol.* 2018;20(3).
11. Guideline on exposure to medicinal products during pregnancy: need for post-authorisation data. European Medicines Agency (EMA).
12. Nguyen J, et al. A review of antibiotic safety in pregnancy: 2025 update. *Pharmacoepidemiol Drug Saf.* 2025.

13. Creeley CE, Denton LK. Use of prescribed psychotropics during pregnancy: a systematic review. *Brain Sci.* 2019;9(9):235.
14. Ardissino M, Slob EAW, Rajasundaram S, et al. Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: Mendelian randomization. *BMC Med.* 2022;20:288.
15. Almuhareb A, Al Sharif A, Cahusac P. Knowledge, attitude, and practice of medication use among pregnant women. *Front Glob Womens Health.* 2024.
16. Chaudhari PV, Jadhav R, Jain A, et al. A comprehensive review on drug-induced diseases and teratogenicity. *Prospects Pharm Sci.* 2025;23(1).
17. Liabsuetrakul T, Yamamoto Y, Kongkamol C, et al. Medications for preventing hypertensive disorders in high-risk pregnant women: a systematic review and network meta-analysis. *Syst Rev.* 2022;11:135.
18. Jonnalagadda D, Kanchana D, Likitha B, et al. Drug safety in pregnancy and lactation: a review of current guidelines. *Int J Res Pharmacol Pharmacother.* 2025;14(1):227–231.